









































125. Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. *Diabetes Care* 30:1374–1383, 2007
126. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr., Selby JV: Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. *JAMA* 301:1565–1572, 2009
127. Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffe T, Seaquist ER, Ismail-Beigi F, Sullivan MD, Lovato LC, Bergenstal RM, Gerstein HC; ACCORD Group of Investigators; ACCORD-MIND Investigators: Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. *Diabetes Care* 35:787–793, 2012
128. Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 374:1677–1686, 2009
129. Luchsinger JA, Ma Y, Florez H, Manly JJ, Golden SH, Hazuda H, Crandall J, Venditti EM, Watson K, Jeffries S, Pi-Sunyer X: Cognition in the Diabetes Prevention Program Outcomes Study (DPPOS). *Diabetes* 63(Suppl 1):A88, 2014
130. de la Monte SM, Wands JR: Alzheimer's disease is type 3 diabetes—evidence reviewed. *J Diabetes Sci Technol* 2:1101–1113, 2008
131. Yki-Jarvinen H: Thiazolidinediones. *N Engl J Med* 351:1106–1118, 2004
132. Nathan DM: Rosiglitazone and cardiotoxicity—weighing the evidence. *N Engl J Med* 357:64–66, 2007
133. Luchsinger JA: Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? *J Alzheimers Dis* 20:723–736, 2010
134. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* 298:1180–1188, 2007
135. Hildreth KL, Van Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, Kittelson J, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS: Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. *Dement Geriatr Cogn Dis Extra* 5:51–63, 2015
136. Nathan DM, Berkwitz M: Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. *Ann Intern Med* 146:461–463, 2007
137. Bailey CJ, Turner RC: Metformin. *N Engl J Med* 334:574–579, 1996
138. Dunn CJ, Peters DH: Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. *Drugs* 49:721–749, 1995
139. Ferrannini E: The target of metformin in type 2 diabetes. *N Engl J Med* 371:1547–1548, 2014
140. Tian J, Shi J, Bailey K, Lendon CL, Pickering-Brown SM, Mann DM: Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 75:696–699, 2004
141. Nathan DM: Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 347:1342–1349, 2002
142. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF: Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. *Proc Natl Acad Sci U S A* 106:3907–3912, 2009
143. Gupta A, Bisht B, Dey CS: Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. *Neuropharmacology* 60:910–920, 2011
144. Imfeld P, Bodmer M, Jick SS, Meier CR: Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. *J Am Geriatr Soc* 60:916–921, 2012
145. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoec C, Rowe C, Watters DA; AIBL Investigators: Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care* 36:2981–2987, 2013
146. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN: Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. *J Alzheimers Dis* 24:485–493, 2011
147. Perez T, Thareja S, Arana E, Chang H, Bagiela E, Luchsinger JA: Phase II clinical trial of metformin in amnesic MCI: rationale, methods, and barriers and enablers of successful recruitment. *J Nutr Health Aging* 15(Suppl 1):S14, 2011
148. Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, Ichise M, Manly J, Devanand D, Bagiella E: Metformin in amnesic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. *J Alzheimers Dis* 51:501–514, 2016
149. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroot W, Mehta P, Craft S: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. *Neurology* 70:440–448, 2008
150. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 133:73–74, 2000
151. Friedrich MJ: New research on Alzheimer treatments ventures beyond plaques and tangles. *JAMA* 308:2553–2555, 2012
152. Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S: Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. *J Neurosci* 30:13110–13115, 2010
153. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. *Am J Epidemiol* 145:301–308, 1997
154. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Arch Neurol* 61:661–666, 2004
155. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K: Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 64:277–281, 2005
156. Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA: Type 2 diabetes and late-onset Alzheimer's disease. *Dement Geriatr Cogn Disord* 31:424–430, 2011